Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from CSPC Pharmaceutical Group ( (HK:1093) ).
CSPC Pharmaceutical Group has secured drug registration approval in mainland China for its Clevidipine Injectable Emulsion, a fast-acting intravenous antihypertensive drug indicated for patients whose hypertension cannot be effectively managed with oral therapy. The formulation offers rapid, precise blood pressure control, does not require dose adjustments for patients with hepatic or renal dysfunction, and can be administered without dilution, addressing clinical needs in hypertensive emergencies. The new approval broadens CSPC’s cardiovascular product pipeline, strengthens its competitive position in this high-value therapeutic segment, and is expected to help meet unmet demand for acute-care hypertension treatments in Chinese hospitals.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.50 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical company focused on developing, manufacturing and marketing a broad range of medicines, with an expanding portfolio in key therapeutic areas such as cardiovascular disease. Listed on the Hong Kong Stock Exchange, the group pursues innovation-driven growth in China’s healthcare market through the development of advanced formulations and hospital-use injectable products.
YTD Price Performance: 13.88%
Average Trading Volume: 120,526,022
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$110.4B
Find detailed analytics on 1093 stock on TipRanks’ Stock Analysis page.